An integrated valuation model for payer and investor
Background In order to optimize positioning and associated drug price for both payer and investor, it is for a company essential to forecast the potential market access attractiveness for the new drug for different indications at the early onset of the clinical development program. This analysis mus...
Saved in:
| Main Authors: | Mark Nuijten, Stefano Capri |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20016689.2022.2080631 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Asset Valuation Concept
by: N. V. Tkachuk
Published: (2024-06-01) -
Problems of western discount rate calculation models application in the process of Russian companies business valuation
by: A. A. Myskin
Published: (2020-07-01) -
Business analysis and valuation : text & cases /
by: Palepu, Krishna G., 1954-
Published: (2010) -
Role of real estate valuation in the management of property of business entities
by: O. E. Astafyeva, et al.
Published: (2025-03-01) -
Public perceptions of high-cost cancer drugs and the implications for reimbursement decisions
by: Youran Noh, et al.
Published: (2025-07-01)